IDGGW (Interpace Biosciences) COGS-to-Revenue : 0.36 (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is Interpace Biosciences COGS-to-Revenue?

Interpace Biosciences's Cost of Goods Sold for the three months ended in Mar. 2025 was $4.15 Mil. Its Revenue for the three months ended in Mar. 2025 was $11.52 Mil.

Interpace Biosciences's COGS to Revenue for the three months ended in Mar. 2025 was 0.36.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Interpace Biosciences's Gross Margin % for the three months ended in Mar. 2025 was 64.00%.

Interpace Biosciences COGS-to-Revenue Historical Data

The historical data trend for Interpace Biosciences's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences COGS-to-Revenue Chart

Interpace Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.67

0.43

0.37

0.36

Interpace Biosciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.38	0.38	0.39	0.28	0.36

Interpace Biosciences COGS-to-Revenue Calculation

Interpace Biosciences's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	17.001	/	46.926
	=	0.36

Interpace Biosciences's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	4.145	/	11.515
	=	0.36

Interpace Biosciences (OTCPK:IDGGW) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Interpace Biosciences's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	4.145 / 11.515
	=	64.00 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Interpace Biosciences COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Interpace Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (OTCPK:IDGGW) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

IDXG:USA PF42:Germany

Address

2001 Route 46, Suite 310, Waterview Plaza, Parsippany, NJ, USA, 07054

Website

https://www.interpace.com

Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer, PancraGEN for pancreatic and biliary cancer, RespriDx for lung cancer, and BarreGEN for the detection of esophageal cancer.